Oramed Pharmaceuticals (ORMP) was Reiterated by FBR Capital to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 20 from a previous price target of $15 . FBR Capital advised their investors in a research report released on May 26, 2016.
Oramed Pharmaceuticals opened for trading at $8.88 and hit $8.98 on the upside on Wednesday, eventually ending the session at $8.92, with a gain of 0.68% or 0.06 points. The heightened volatility saw the trading volume jump to 1,96,063 shares. Company has a market cap of $117 M.
In a different news, on May 12, 2016, Nadav Kidron (CEO) purchased 1,000 shares at $6.98 per share price. According to the SEC, on Mar 14, 2016, Harold Jacob (director) sold 8,500 shares at $6.45 per share price. On Dec 31, 2015, Miriam Kidron (Chief Technology Officer) sold 50,000 shares at $8.98 per share price, according to the Form-4 filing with the securities and exchange commission.
Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Orameds flagship product an orally ingestible insulin capsule in phase II clinical trials is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Orameds delivery platform protects protein sand enhances their absorption allowing them to reach the blood stream through the portal vein. The Companys products include ORMD-0801 Oral insulin capsule; ORMD 0901 Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.